Citron exposes explosive findings behind the true components of Questcor Pharmaceuticals Inc (NASDAQ:QCOR) flagship drug HP Acthar Gel. Questcor Pharmaceuticals Inc. (NASDAQ:QCOR) stock performance was -9.96% in last session and finished the day at $60.75. Traded volume was 0.00 shares in the last session and the average volume of the stock remained 2.86 million shares. The beta of the stock remained 0.95. Questcor Pharmaceuticals Inc. (NASDAQ:QCOR) insider ownership is 1.40%.

ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in neurological and related central nervous system. ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) dropped -5.98% to $28.30 yesterday on volume of 0.00 shares. The intra-day range of the stock was $27.00 – $32.00. ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) has a market capitalization of 2.53 billion.

Idera Pharmaceuticals, Inc., a clinical stage biotechnology company, engages in the discovery and development of novel synthetic DNA- and RNA- based drug candidates. Idera Pharmaceuticals Inc. (NASDAQ:IDRA)’s stock on February 28, 2014 reported a lower of -6.76% to the closing price of $5.79. Its fifty two weeks range is $0.19 – $6.75. The total market capitalization recorded 264.72 million. The overall volume in the last trading session was 0.00 shares. In its share capital, Idera Pharmaceuticals Inc. (NASDAQ:IDRA) has 45.72 million outstanding shares.

Celldex Therapeutics, Inc. (NASDAQ:CLDX) will release fourth quarter and year end 2013 financial results on Monday, March 3, 2014 before the U.S. On Friday, shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX) dropped -7.50% to close the day at $29.22. Company return on investment (ROI) is -54.20% and its monthly performance is recorded as 15.31%. Celldex Therapeutics, Inc. (NASDAQ:CLDX) quarterly revenue growth is 7.74%.